IFF first quarter
This article was originally published in The Rose Sheet
Executive Summary
North American functional fragrance sales rose 20% in Q1 based on "new wins," but 20% decline in fine fragrance revenues led to flat fragrance performance overall for the region, excluding businesses divested in 2001, Chief Financial Officer Doug Wetmore states during April 25 financial report. European fragrance sales declined 1% in dollar terms, pulled down by high single-digit decrease in fine fragrances. Worldwide fragrance sales off 3% during quarter on pro forma basis, excluding businesses sold in late 2001 and reflecting new accounting rules for goodwill and intangibles, according to firm's April 25 1sales and earnings release. Consolidated sales of $445.8 mil. for Q1 were down 3.9% on pro forma basis. Net earnings doubled to $41.9 mil., up from $20.3 mil. in previous-year period...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.